阿托伐他汀钙结合非诺贝特药物治疗冠心病的临床价值

doi:10.3969/j.issn.1001-8131.2024.01.003

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (559 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical value of atorvastatin calcium combined with fenofibrate in the treatment of coronary atherosclerotic heart disease（CHD）. Methods A total of 82 cases of CHD patient were selected and divided into a combination group（n=41）and a single group（n=41）by random number table method.The single group was treated with atorvastatin calcium,and the combined group was treated with fenofibrate on the basis of a single group.The therapeutic effect,blood lipid levels [total cholesterol（TC）,high-density lipoprotein cholesterol（HDL-C）,triglyceride（TG）],carotid intimax-media thickness（IMT）,vascular endothelial function [nitric oxide（NO）,endothelin-1（ET-1）],cardiac function [left ventricular end-systolic diameter（LVESD）,and left ventricular ejection fraction（LVEF）] were compared between the two groups Number and the incidence of adverse reactions. Results The total effective rate of the combination group95.12%（39/41）was higher than that of the single group 80.49%（33/41）（P<0.05）.After treatment,the TC and TG levels in the combination group were lower than those in the single group,and the HDL-C level was higher than those in the single group（P<0.05）.After treatment,the level of carotid IMT in the combination group was lower than that in the single group（P<0.05）.After treatment,the ET-1 level in the combination group was lower than that in the single group,and the NO level was higher than that in the single group（P<0.05）.After treatment,the LVEF level in the combination group was higher than that in the single group,and the LVESD level was lower than that in the single group（P<0.05）.There was no significant difference in adverse reactions between the two groups（P>0.05）. Conclusion Fenofibrate combined with atorvastatin calcium in the treatment of CHD patients can improve the efficacy,reduce the blood lipid levels and carotid IMT thickness,and improve the vascular endothelial function and cardiac function,which is safe and reliable.

Key words： Atorvastatin calcium Fenofibrate Coronary atherosclerotic heart disease Cardiac function

Received: 20 February 2023

PACS:

R541.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Hou Bin
	Zheng Fangfang

Cite this article:

Hou Bin,Zheng Fangfang. Clinical Value of Atorvastatin Calcium Combined with Fenofibrate in the Treatment of Coronary Atherosclerotic Heart Disease[J]. journal1, 2024, 44(1): 11-14.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2024.01.003 OR http://www.hrbyybjb.org.cn/EN/Y2024/V44/I1/11

[1] 韩宁宁. 阿托伐他汀钙联合苯磺酸左旋氨氯地平治疗高血压合并冠心病的临床疗效及不良反应观察[J].贵州医药,2021,45(7):1102-1103.
[2] 黄焯文,林利珍,董浩亮,等.曲美他嗪联合阿托伐他汀治疗冠心病心绞痛的疗效及对患者血脂代谢的影响[J].临床医学,2021,41(8):92-94.
[3] 台来提·吐尔洪.不同剂量阿托伐他汀联合二丁酰环磷酰苷钙对冠心病合并慢性心衰患者心功能及NT—proBNP的影响[J].新疆医学,2018,48(10):1086-1088.
[4] 张月超. 硫酸氢氯吡格雷片联合阿托伐他汀钙对冠心病PCI术后心绞痛患者血清血脂水平、sCD40L及sICAM-1水平的影响[J].标记免疫分析与临床,2019,26(7):1200-1203,1227.
[5] 魏征,徐飞,周勇.麝香保心丸联合阿托伐他汀钙治疗冠心病心力衰竭的效果观察及对心功能的影响[J].湖南师范大学学报(医学版),2021,18(4):124-127.
[6] 穆万丹,黄丹,何渝.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病患者血压水平及心功能的影响[J].中国医院药学杂志,2021,41(6):641-644.
[7] 王震,张方霞,李宗清,等.通心络胶囊结合非洛地平治疗冠心病心绞痛的疗效及对NT-pro BNP、sCD105水平的影响[J].中华中医药学刊,2021,39(12):193-196.
[8] 沈迎,张奇,沈卫峰.美国和欧洲稳定性冠心病诊治指南解读[J].中华心血管病杂志,2014,42(1):70-72.
[9] 莫文宏,凌剑帆,赵生海,等.阿托伐他汀钙联合银杏达莫对冠心病合并高胆固醇血症病人血管内皮功能及血流动力学的影响[J].中西医结合心脑血管病杂志,2019,17(10):1516-1519.
[10] 宋晓燕,张毅,雷小宝,等.不同剂量阿托伐他汀钙治疗对冠心病合并高血压患者血脂、血管内皮功能及动态血压水平的影响[J].海南医学,2021,32(21):2736-2739.
[11] 张文,肖勇,高妍,等.不同剂量阿托伐他汀联合二丁酰环磷酰苷钙对冠心病合并慢性心衰患者心功能及NT-proBNP的影响[J].中国心血管病研究,2018,16(1):64-68.
[12] 贾德权,魏晓梅,李培伦.老年冠心病接受支架置入患者治疗中序贯与强化剂量阿托伐他汀对临床疗效及血清学指标的影响[J].中国循证心血管医学杂志,2019,11(5):623-626.